Updated July 2026. Scope: medical device regulatory concepts, U.S. FDA and EU MDR/IVDR. For the foundational definitions, see the guide on intended use and indications for use.
Key takeaways
- Intended use, indications for use, and claims are three different things. Teams that treat them as synonyms end up with the wrong classification, the wrong submission scope, or promotion that outruns what was cleared.
- Intended use is the objective purpose of the device, judged by what the manufacturer says and does, not by private intent (21 CFR 801.4). In the EU it is the device’s intended purpose (MDR Article 2(12)).
- Indications for use are narrower: the specific disease or condition, and the patient population, the device is for.
- Claims are the statements you make about the device. Under 801.4, claims and advertising are evidence of intended use, so a claim can expand your intended use whether you meant it to or not.
Intended use: the objective-intent standard
Intended use is not what you privately meant. Under 21 CFR 801.4, intended use is the objective intent of the persons legally responsible for the labeling, shown through labeling claims, advertising, oral or written statements, the design or composition of the device, and the circumstances of its distribution. FDA reads intent from the outside, from what you publish and how the device is sold.
Two points from the current rule matter in practice:
- A firm is not deemed to intend an unapproved use merely because it knows healthcare providers use an approved device in another way. Knowledge of off-label use alone does not create a new intended use.
- If a downstream distributor or seller intends a different use than the original manufacturer, they must provide labeling adequate for that new intended use.
In the EU, the parallel concept is the device’s intended purpose (MDR Article 2(12)): the use for which the device is intended according to the manufacturer’s label, instructions for use, promotional or sales materials or statements, and the clinical evaluation. Same idea, same source of truth: your own materials.
Indications for use: the specific conditions
Indications for use are narrower than intended use. They state the specific disease or condition the device diagnoses, treats, prevents, cures, or mitigates, and the patient population it is for. In an FDA submission, the Indications for Use statement is a defined, bounded description, not a general purpose.
The relationship is a nesting one:
| Concept | Scope | Example shape |
|---|---|---|
| Intended use / intended purpose | The general purpose of the device | What the device is for, broadly |
| Indications for use | The specific conditions and population | The exact disease, setting, and patients |
| Claims | The statements made about the device | What marketing, labeling, and sales say |
A device can have one intended use and several indications, and every claim should sit inside what the indications and the underlying evidence support.
Claims: where intended use quietly expands
Claims are the statements you make in labeling, advertising, a website, a sales deck, or a booth conversation. Because 21 CFR 801.4 treats claims and advertising as evidence of intended use, a claim that reaches beyond your cleared or CE-marked indications can create a new intended use in the regulator’s eyes. That is the mechanism behind two common problems:
- Off-label promotion. Promoting a device for a use outside its cleared indications is promoting a new intended use that was never assessed.
- Scope creep before submission. Marketing language drafted ahead of the regulatory strategy can lock in a broader intended use than the evidence supports, forcing either new evidence or a walk-back.
The fix is sequence. Decide the intended use and indications first, build the evidence to match, then write claims that stay inside them. Claims are the output of the regulatory position, not the input.
Why the distinction decides real things
The three concepts are not academic. They drive:
- Classification. Intended use and indications determine the device’s risk class and regulatory pathway. A broader intended use can move a device into a higher class or a different route.
- Submission scope. Indications for use bound what a 510(k), De Novo, PMA, or EU technical documentation has to support. Get them wrong and the submission is either over-built or short.
- Promotional risk. Claims outside the cleared or CE-marked indications are a misbranding and off-label-promotion exposure, not a marketing nuance.
Aligning the three is regulatory strategy work, not copywriting. It belongs at the start of a program, before the evidence plan and long before the launch deck.
Frequently asked questions
What is the difference between intended use and indications for use?
Intended use is the general purpose of the device, judged objectively from your labeling, advertising, and how the device is sold (21 CFR 801.4). Indications for use are narrower: the specific disease or condition and patient population the device is for. Indications sit inside the intended use.
Can a marketing claim change my intended use?
Yes. Under 21 CFR 801.4, claims and advertising are evidence of intended use. A claim that reaches beyond your cleared indications can establish a new intended use that was never assessed, which is how off-label promotion happens.
Is intended use the same in the EU?
The concept is the same, under a different name. The EU MDR uses “intended purpose” (Article 2(12)): the use for which the device is intended according to the manufacturer’s label, instructions for use, promotional or sales materials or statements, and the clinical evaluation.
Does FDA knowing about off-label use create a new intended use?
No. Under the current 21 CFR 801.4, a firm is not deemed to intend an unapproved use merely because it knows providers use an approved device in another way.
When should we lock the intended use and indications?
At the start, before the evidence plan and the marketing. Classification, submission scope, and promotional risk all follow from them, so drafting claims first tends to force expensive rework.
Related guides and services
- Regulatory Affairs support from CENIT Consulting: intended use and indications work, classification, and the regulatory strategy that keeps claims inside the evidence.
- For the foundational definitions, see intended use and indications for use.
This article is for general information only and is not legal or regulatory advice. Teams remain responsible for regulatory decisions and staying current with applicable regulations and guidance.
Talk to CENIT Consulting about locking your intended use and indications before submission: book a 30-minute consult.